Published in Medical Letter on the CDC and FDA, February 21st, 2010
"The SPA enables us to initiate this carfilzomib Phase 3 combination trial in the first half of this year...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA